NGM Biopharmaceuticals Investor Relations Material
Latest events
Study Result
NGM Biopharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from NGM Biopharmaceuticals Inc
Access all reports
NGM Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of liver and metabolic diseases, retinal diseases, and cancer. The company's key products in development include NGM707, a dual antagonist monoclonal antibody for advanced metastatic solid tumors, and Aldafermin, an engineered analog of a human hormone aimed at treating liver diseases such as non-alcoholic steatohepatitis. Additionally, NGM Biopharmaceuticals works on a variety of other drug candidates targeted at different therapeutic areas, using a biologics-based platform to create and evaluate monoclonal antibodies and other proteins. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
The Brunello Cucinelli Story: Combining Elegance and Ethics
Explore the success of Brunello Cucinelli's unique blend of luxury craftsmanship and ethical business.
14 May 2024
Amazon's Most Notable Acquisitions Since Inception
Explore Amazon's most impactful acquisitions, from IMDb and Zappos to Whole Foods and MGM, and how these have diversified its business.
13 May 2024
Adidas vs Puma: The Story of the Dassler Brothers
An in-depth article outlining the story of the Dassler brothers, their feud with one another, and the history of Puma and Adidas.
10 May 2024
Ticker symbol
Country
đșđž United States